Ensign Peak Advisors
ACET icon

Ensign Peak Advisors’s Adicet Bio ACET Stock Holding History

Ensign Peak Advisors’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,837
Closed -$1.56M – 1787
2022
Q3 		$1.56M Buy
6,837
+686
+11% +$174K ﹤0.01% 868
2022
Q2 		$1.44M Buy
6,151
+4,692
+322% +$1.03M ﹤0.01% 948
2022
Q1 		$466K Buy
+1,459
New +$336K ﹤0.01% 1579

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Ensign Peak Advisors's ACET Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Adicet Bio (ACET) in Q4 2022, closing a stake of 6,837 shares — an estimated $1.56M sold.

Ensign Peak Advisors first reported a position in ACET in Q1 2022 and held it in 3 quarters. The position peaked at $1.56M in Q3 2022. 100 funds tracked by Wall St. Rank hold ACET as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Adicet Bio position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 6,837 Adicet Bio shares in Q4 2022, an estimated $1.56M.
  • Ensign Peak Advisors first reported a position in Adicet Bio in Q1 2022 and held it in 3 quarters.
  • Ensign Peak Advisors's Adicet Bio position peaked at $1.56M in Q3 2022.
  • 100 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.